Literature DB >> 26577851

TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer.

Francesca Coperchini1, Patrizia Pignatti2, Andrea Carbone1, Rossana Bongianino3, Christian A Di Buduo4,5, Paola Leporati1, Laura Croce1, Flavia Magri1, Alessandra Balduini4,5,6, Luca Chiovato7, Mario Rotondi1.   

Abstract

The chemokine receptor CCR6, selectively bound by CCL20, is involved in the metastatic spread of cancer cells. Tumor necrosis factor-α (TNF-α) displays a complex pro-tumorigenic actions, but it is unknown whether this cytokine could modulate the expression of chemokine receptors in thyroid tumors. The membrane expression of CCR6 was assessed by flow cytometry and immunofluorescence, in primary cultures of normal human thyroid (NHT) cells and in thyroid cancer cell lines (TPC-1 and BCPAP), both in basal conditions and after stimulation with TNF-α. In basal conditions, CCR6+ cells were virtually absent in NHT cells (0.4 ± 0.4 %), while they were detected in TPC-1 (23.6 ± 6.6 %) and in BCPAP (12.9 ± 9.4 %) tumor cells (ANOVA F: 10.534; p < 0.005). The incubation with TNF-α significantly increased the percentage of CCR6+ cells in TPC-1 (23.6 ± 6.6 % vs. 33.1 ± 8.7; p < 0.033) and in BCPAP (12.9 ± 9.4 % vs. 18.1 ± 11.5; p < 0.030), but not in NHT (0.4 ± 0.4 % vs. 0.2 ± 0.3; NS) cells. The magnitude of the TNF-α effect was similar for TPC-1 and BCPAP (∼40 % vs. baseline) cells. TPC-1 cells were characterized by a greater amount of CCR6 per cell as compared with BCPAP cells, both in basal conditions (148.3 ± 33.7 fluorescence intensity vs. 102.5 ± 22.1 p < 0.016) and after TNF-α stimulation (147.8 ± 46.3 fluorescence intensity vs. 95.3 ± 18.5; p < 0.025). Cell migration assays showed that TNF-α treatment significantly increased the rate of migrated cells in those cells in which it also increased the membrane expression of CCR6 (TPC-1 and BCPAP) as compared to basal condition (p < 0.05 for both TPC-1 and BCPAP cells). No effect was observed in NHT cells in which TNF-α stimulation had no effect in terms of CCR6 expression. We first report that TNF-α enhances the expression of CCR6 in thyroid tumor cells, thus providing evidence that TNF-α increases the metastatic potential of thyroid tumors.

Entities:  

Keywords:  CCR6; Chemokine receptor; Thyroid cancer; Thyroid cancer cell lines; Tumor necrosis factor-α

Mesh:

Substances:

Year:  2015        PMID: 26577851     DOI: 10.1007/s13277-015-4418-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  L-selectin can facilitate metastasis to lymph nodes in a transgenic mouse model of carcinogenesis.

Authors:  F Qian; D Hanahan; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Chemokine receptor CCR6 expression in colorectal liver metastasis.

Authors:  Claudia Rubie; Vilma Oliveira-Frick; Bettina Rau; Martin Schilling; Mathias Wagner
Journal:  J Clin Oncol       Date:  2006-11-10       Impact factor: 44.544

Review 3.  Chemokines as targets for therapy.

Authors:  Alexandre Garin; Amanda E I Proudfoot
Journal:  Exp Cell Res       Date:  2011-03-10       Impact factor: 3.905

4.  Discoidin domain receptor 1 protein is a novel modulator of megakaryocyte-collagen interactions.

Authors:  Vittorio Abbonante; Cristian Gruppi; Diana Rubel; Oliver Gross; Remigio Moratti; Alessandra Balduini
Journal:  J Biol Chem       Date:  2013-03-24       Impact factor: 5.157

Review 5.  Chemokines: agents for the immunotherapy of cancer?

Authors:  Bernhard Homey; Anja Müller; Albert Zlotnik
Journal:  Nat Rev Immunol       Date:  2002-03       Impact factor: 53.106

Review 6.  Interleukin-8 and human cancer biology.

Authors:  K Xie
Journal:  Cytokine Growth Factor Rev       Date:  2001-12       Impact factor: 7.638

7.  Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug.

Authors:  Mario Rotondi; Francesca Coperchini; Patrizia Pignatti; Flavia Magri; Luca Chiovato
Journal:  J Clin Endocrinol Metab       Date:  2015-01-15       Impact factor: 5.958

Review 8.  Molecular networks that regulate cancer metastasis.

Authors:  Daniela Spano; Chantal Heck; Pasqualino De Antonellis; Gerhard Christofori; Massimo Zollo
Journal:  Semin Cancer Biol       Date:  2012-03-30       Impact factor: 15.707

Review 9.  Thyroid cancer and inflammation.

Authors:  Valentina Guarino; Maria Domenica Castellone; Elvira Avilla; Rosa Marina Melillo
Journal:  Mol Cell Endocrinol       Date:  2009-10-14       Impact factor: 4.102

10.  A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma.

Authors:  M Takenaga; H Tamamura; K Hiramatsu; N Nakamura; Y Yamaguchi; A Kitagawa; S Kawai; H Nakashima; N Fujii; R Igarashi
Journal:  Biochem Biophys Res Commun       Date:  2004-07-16       Impact factor: 3.575

View more
  8 in total

1.  Role of papillary thyroid carcinoma patients with Hashimoto thyroiditis: evaluation of oxidative stress and inflammatory markers.

Authors:  Natália Medeiros Dias Lopes; Hannah Hamada Mendonça Lens; Walison Augusto da Silva Brito; Julya Karen Bianchi; Poliana Camila Marinello; Rubens Cecchini; André Armani; Alessandra Lourenço Cecchini
Journal:  Clin Transl Oncol       Date:  2022-07-28       Impact factor: 3.340

2.  The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration.

Authors:  O Awwad; F Coperchini; P Pignatti; M Denegri; S Massara; L Croce; C A Di Buduo; V Abbonante; A Balduini; L Chiovato; M Rotondi
Journal:  J Endocrinol Invest       Date:  2018-03-15       Impact factor: 4.256

3.  Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.

Authors:  Mario Rotondi; Francesca Coperchini; Oriana Awwad; Patrizia Pignatti; Christian A Di Buduo; Vittorio Abbonante; Flavia Magri; Alessandra Balduini; Luca Chiovato
Journal:  Mediators Inflamm       Date:  2016-07-31       Impact factor: 4.711

Review 4.  Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?

Authors:  Mario Rotondi; Francesca Coperchini; Francesco Latrofa; Luca Chiovato
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-21       Impact factor: 5.555

5.  A case report on filamin A gene mutation and progressive pulmonary disease in an infant: A lung tissued derived mesenchymal stem cell study.

Authors:  Valeria Calcaterra; Maria Antonietta Avanzini; Melissa Mantelli; Emanuele Agolini; Stefania Croce; Annalisa De Silvestri; Giuseppe Re; Mirella Collura; Alice Maltese; Antonio Novelli; Gloria Pelizzo
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

6.  The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors.

Authors:  Francesca Coperchini; Laura Croce; Marco Denegri; Oriana Awwad; Samuel Tata Ngnitejeu; Marina Muzza; Valentina Capelli; Francesco Latrofa; Luca Persani; Luca Chiovato; Mario Rotondi
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

7.  Common transcriptional programs and the role of chemokine (C-C motif) ligand 20 (CCL20) in cell migration of cholangiocarcinoma.

Authors:  Hay Mar Win Maung; Waraporn Chan-On; Nawapol Kunkeaw; Prasong Khaenam
Journal:  EXCLI J       Date:  2020-01-20       Impact factor: 4.068

8.  Nevirapine Increases Sodium/Iodide Symporter-Mediated Radioiodide Uptake by Activation of TSHR/cAMP/CREB/PAX8 Signaling Pathway in Dedifferentiated Thyroid Cancer.

Authors:  Hongxia Shang; Junyu Zhao; Jinming Yao; Huanjun Wang; Jianjun Dong; Lin Liao
Journal:  Front Oncol       Date:  2020-03-31       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.